Core Viewpoint - The announcement highlights a significant licensing agreement between Jiangsu Xiansheng and Ipsen Pharma for the ADC SIM0613, indicating a strategic partnership aimed at expanding the drug's market reach outside Greater China [1] Group 1: Licensing Agreement Details - Jiangsu Xiansheng has signed an exclusive licensing agreement with Ipsen Pharma for the global development, production, and commercialization rights of the ADC SIM0613 outside Greater China [1] - The agreement allows Jiangsu Xiansheng to receive up to $1.06 billion, which includes a $45 million upfront payment, milestone payments related to research, regulatory, and commercialization, as well as tiered royalties on sales [1] Group 2: Product Information - SIM0613 is a novel antibody-drug conjugate targeting LRRC15, a protein highly expressed on the surface of various solid tumors and cancer-associated fibroblasts, but minimally expressed in normal cells [1] - The mechanism of SIM0613 involves binding to LRRC15, leading to internalization into tumor cells and the release of cytotoxic payloads, effectively killing tumor cells while sparing normal cells [1] - The design of SIM0613 allows for deep penetration into tumors and cancer-associated fibroblasts, demonstrating significant tumor regression effects in various preclinical in vivo models [1]
先声药业(02096.HK)：与Ipsen就SIM0613(LRRC15抗体偶联药物)签订独家授权许可协议